IL17A and influenza: Furthermore, in the lung tissue of mice with influenza, the novel fusion protein vunakizumab-IL22 (vmab-IL-22), a conjugate of IL-22 with anti-IL-17A antibodies, can inhibit IL-17A-mediated inflammatory responses and elevate the reparative capacity of IL-22 [173].